Healthcare provider profile · identity verified

Lindsay Maudrie, P.A.

Physician Assistant · WYANDOTTE, MI · NPI 1730413113

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	190	77
Lisinopril	Lisinopril	154	49
Albuterol Sulfate Hfa	Albuterol Sulfate	95	39
Levothyroxine Sodium	Levothyroxine Sodium	92	35
Amlodipine Besylate	Amlodipine Besylate	89	36
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	89	34
Simvastatin	Simvastatin	81	28
Alprazolam	Alprazolam	77	22
Omeprazole	Omeprazole	77	35
Gabapentin	Gabapentin	76	28
Lorazepam	Lorazepam	76	29
Metformin Hcl	Metformin Hcl	71	29
Furosemide	Furosemide	68	27
Ozempic	Semaglutide	64	14
Metoprolol Succinate	Metoprolol Succinate	63	27
Sertraline Hcl	Sertraline Hcl	63	23
Losartan Potassium	Losartan Potassium	54	21
Metoprolol Tartrate	Metoprolol Tartrate	46	19
Potassium Chloride	Potassium Chloride	44	17
Tramadol Hcl	Tramadol Hcl	43	16
Trazodone Hcl	Trazodone Hcl	40	15
Hydrochlorothiazide	Hydrochlorothiazide	39	18
Allopurinol	Allopurinol	37	15
Rosuvastatin Calcium	Rosuvastatin Calcium	36	16
Pantoprazole Sodium	Pantoprazole Sodium	34	17
Tamsulosin Hcl	Tamsulosin Hcl	34	12
Montelukast Sodium	Montelukast Sodium	30	11
Xarelto	Rivaroxaban	30	11
Carvedilol	Carvedilol	29	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	11
Duloxetine Hcl	Duloxetine Hcl	29	suppressed
Ibuprofen	Ibuprofen	29	19
Atenolol	Atenolol	28	suppressed
Azithromycin	Azithromycin	28	28
Clopidogrel	Clopidogrel Bisulfate	27	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	26	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Prednisone	Prednisone	25	17
Tizanidine Hcl	Tizanidine Hcl	25	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Ventolin Hfa	Albuterol Sulfate	24	12
Clonazepam	Clonazepam	23	suppressed
Eliquis	Apixaban	23	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	20	suppressed
Glipizide	Glipizide	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	15
Diazepam	Diazepam	19	suppressed
Famotidine	Famotidine	19	11
Glipizide Er	Glipizide	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	15
Fluticasone Propionate	Fluticasone Propionate	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Temazepam	Temazepam	17	suppressed
Aripiprazole	Aripiprazole	16	suppressed
Fluconazole	Fluconazole	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Meclizine Hcl	Meclizine Hcl	15	11
Memantine Hcl	Memantine Hcl	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Jardiance	Empagliflozin	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Nystatin	Nystatin	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Butalb-Acetaminoph-Caff-Codein	Butalbit/Acetamin/Caff/Codeine	12	suppressed
Finasteride	Finasteride	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error